BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
In This Article:
BridgeBio's new heart drug — a rival to Pfizer's blockbuster Vyndaqel — smashed sales expectations in its first full quarter on the market.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
BridgeBio's new heart drug — a rival to Pfizer's blockbuster Vyndaqel — smashed sales expectations in its first full quarter on the market.